Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07743489 Rose Bengal disodium Ulcer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07743489 clinical trial report covering Rose Bengal disodium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07745296 Futibatinib Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07745296 clinical trial report covering Futibatinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
Abgenix, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Abgenix, Inc BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Latest Hotspot
8 min read
1910 Genetics Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
1910 Genetics BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
8 min read
Duvax Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Duvax: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Ceforanide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Ceforanide: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IOV-5001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
IOV-5001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
RBN-3143 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
RBN-3143: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Autologous hALK.CAR T cells(The Children's Hospital Corp) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
Autologous hALK.CAR T cells(The Children's Hospital Corp): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
RO-7446603 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
RO-7446603: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IG-3018 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
IG-3018: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ACIT-1 cancer vaccine(Cancer Vaccines Limited) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
5 August 2026
ACIT-1 cancer vaccine(Cancer Vaccines Limited): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.